{"id":"https://openalex.org/W2058514432","doi":"https://doi.org/10.1111/j.1463-1326.2012.01603.x","title":"Glycaemic efficacy of glucagon\u2010like peptide\u20101 receptor agonists and dipeptidyl peptidase\u20104 inhibitors as add\u2010on therapy to metformin in subjects with type 2 diabetes\u2014a review and meta analysis","display_name":"Glycaemic efficacy of glucagon\u2010like peptide\u20101 receptor agonists and dipeptidyl peptidase\u20104 inhibitors as add\u2010on therapy to metformin in subjects with type 2 diabetes\u2014a review and meta analysis","publication_year":2012,"publication_date":"2012-04-03","ids":{"openalex":"https://openalex.org/W2058514432","doi":"https://doi.org/10.1111/j.1463-1326.2012.01603.x","mag":"2058514432","pmid":"https://pubmed.ncbi.nlm.nih.gov/22471248"},"language":"en","primary_location":{"id":"doi:10.1111/j.1463-1326.2012.01603.x","doi":"https://doi.org/10.1111/j.1463-1326.2012.01603.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2012.01603.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054335526","display_name":"Carolyn Fiona Deacon","orcid":"https://orcid.org/0000-0003-2611-5642","observed_orcids":["https://orcid.org/0000-0003-2611-5642"]},"institutions":[{"id":"https://openalex.org/I124055696","display_name":"University of Copenhagen","ror":"https://ror.org/035b05819","country_code":"DK","type":"education","lineage":["https://openalex.org/I124055696"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"C. F. Deacon","raw_affiliation_strings":["Department of Biomedical Sciences, Copenhagen University, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biomedical Sciences, Copenhagen University, Copenhagen, Denmark","institution_ids":["https://openalex.org/I124055696"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059685674","display_name":"Edoardo Mannucci","orcid":"https://orcid.org/0000-0001-9759-9408","observed_orcids":["https://orcid.org/0000-0001-9759-9408"]},"institutions":[{"id":"https://openalex.org/I4210115393","display_name":"Azienda Ospedaliero-Universitaria Careggi","ror":"https://ror.org/02crev113","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210115393"]},{"id":"https://openalex.org/I45084792","display_name":"University of Florence","ror":"https://ror.org/04jr1s763","country_code":"IT","type":"education","lineage":["https://openalex.org/I45084792"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"E. Mannucci","raw_affiliation_strings":["Diabetes Agency, Careggi Teaching Hospital, Florence, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Agency, Careggi Teaching Hospital, Florence, Italy","institution_ids":["https://openalex.org/I4210115393","https://openalex.org/I45084792"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027109387","display_name":"Bo \u00c5hr\u00e9n","orcid":"https://orcid.org/0000-0002-9804-5340","observed_orcids":["https://orcid.org/0000-0002-9804-5340"]},"institutions":[{"id":"https://openalex.org/I187531555","display_name":"Lund University","ror":"https://ror.org/012a77v79","country_code":"SE","type":"education","lineage":["https://openalex.org/I187531555"]}],"countries":["SE"],"is_corresponding":true,"raw_author_name":"B. Ahr\u00e9n","raw_affiliation_strings":["Department of Clinical Sciences Lund, Lund University, Lund, Sweden","Dept of Clinical Sciences Lund, Lund Univ, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Sciences Lund, Lund University, Lund, Sweden","institution_ids":["https://openalex.org/I187531555"]},{"raw_affiliation_string":"Dept of Clinical Sciences Lund, Lund Univ, Lund, Sweden","institution_ids":["https://openalex.org/I187531555"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5027109387"],"corresponding_institution_ids":["https://openalex.org/I187531555"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":3.7404,"has_fulltext":false,"cited_by_count":190,"citation_normalized_percentile":{"value":0.96440873,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"14","issue":"8","first_page":"762","last_page":"767"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.968999981880188},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.8679999709129333},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9829999804496765},{"id":"https://openalex.org/keywords/incretin-based-therapy","display_name":"incretin-based therapy","score":0.8159999847412109},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.8899999856948853},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.9570000171661377},{"id":"https://openalex.org/keywords/fasting-blood-glucose","display_name":"fasting blood glucose","score":0.7329999804496765},{"id":"https://openalex.org/keywords/body-weight","display_name":"body weight","score":0.8820000290870667},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":0.8740000128746033},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.996999979019165},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8970000147819519},{"id":"https://openalex.org/keywords/heart-rate","display_name":"heart rate","score":0.3149999976158142},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.3319999873638153}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9185802340507507},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.7883672714233398},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.7068882584571838},{"id":"https://openalex.org/C156490143","wikidata":"https://www.wikidata.org/wiki/Q412214","display_name":"Dipeptidyl peptidase-4","level":4,"score":0.6939098238945007},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.6424979567527771},{"id":"https://openalex.org/C2776398474","wikidata":"https://www.wikidata.org/wiki/Q424611","display_name":"Glucagon-like peptide-1","level":4,"score":0.5531463027000427},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.47563695907592773},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.4592966139316559},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4537326693534851},{"id":"https://openalex.org/C2778763485","wikidata":"https://www.wikidata.org/wiki/Q419770","display_name":"Dipeptidyl peptidase-4 inhibitor","level":4,"score":0.41253039240837097},{"id":"https://openalex.org/C2780282729","wikidata":"https://www.wikidata.org/wiki/Q3121121","display_name":"Saxagliptin","level":5,"score":0.41179537773132324},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.37100619077682495},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.36742788553237915},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.34966760873794556},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.2968294024467468},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.19721895456314087}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000068900","descriptor_name":"Sitagliptin Phosphate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077270","descriptor_name":"Exenatide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005215","descriptor_name":"Fasting","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018027","descriptor_name":"Receptors, Glucagon","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.1111/j.1463-1326.2012.01603.x","doi":"https://doi.org/10.1111/j.1463-1326.2012.01603.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2012.01603.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:22471248","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22471248","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Journal Article"},{"id":"pmh:oai:flore.unifi.it:2158/1023865","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/2158/1023865","pdf_url":null,"source":{"id":"https://openalex.org/S4306402033","display_name":"Florence Research (University of Florence)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I45084792","host_organization_name":"University of Florence","host_organization_lineage":["https://openalex.org/I45084792"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:lup.lub.lu.se:c98c171c-ffb3-429d-9d3e-a2addf8af134","doi":null,"is_oa":false,"landing_page_url":"https://lup.lub.lu.se/record/2519901","pdf_url":null,"source":{"id":"https://openalex.org/S4306400536","display_name":"Lund University Publications (Lund University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I187531555","host_organization_name":"Lund University","host_organization_lineage":["https://openalex.org/I187531555"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ISSN: 1462-8902","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/d49f66bb-9cc0-45fe-85ad-00c56badb2cb","doi":null,"is_oa":false,"landing_page_url":"https://researchprofiles.ku.dk/da/publications/d49f66bb-9cc0-45fe-85ad-00c56badb2cb","pdf_url":null,"source":{"id":"https://openalex.org/S4306401983","display_name":"Research at the University of Copenhagen (University of Copenhagen)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I124055696","host_organization_name":"University of Copenhagen","host_organization_lineage":["https://openalex.org/I124055696"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Deacon, C F, Mannucci, E & Ahren, B 2012, 'Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes\u2014a review and meta analysis', Diabetes, Obesity and Metabolism Online, vol. 14, no. 8, pp. 762-767. https://doi.org/10.1111/j.1463-1326.2012.01603.x","raw_type":"info:eu-repo/semantics/review"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"},{"display_name":"Meta-Analysis","id":"https://openalex.org/study-designs/meta-analysis"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":44,"referenced_works":["https://openalex.org/W91242618","https://openalex.org/W1504967583","https://openalex.org/W1928513790","https://openalex.org/W1967256054","https://openalex.org/W1977619586","https://openalex.org/W1979982110","https://openalex.org/W1984740259","https://openalex.org/W2002800136","https://openalex.org/W2015569637","https://openalex.org/W2027744617","https://openalex.org/W2036167841","https://openalex.org/W2043900831","https://openalex.org/W2051493851","https://openalex.org/W2054185381","https://openalex.org/W2054649558","https://openalex.org/W2055753691","https://openalex.org/W2061691264","https://openalex.org/W2064437324","https://openalex.org/W2068402489","https://openalex.org/W2071835038","https://openalex.org/W2074142099","https://openalex.org/W2079787842","https://openalex.org/W2099092932","https://openalex.org/W2101246901","https://openalex.org/W2102400698","https://openalex.org/W2102511839","https://openalex.org/W2103058881","https://openalex.org/W2103364479","https://openalex.org/W2105926302","https://openalex.org/W2107949845","https://openalex.org/W2113367996","https://openalex.org/W2114927834","https://openalex.org/W2128181185","https://openalex.org/W2141132900","https://openalex.org/W2141848583","https://openalex.org/W2141946042","https://openalex.org/W2147774754","https://openalex.org/W2148495354","https://openalex.org/W2150849997","https://openalex.org/W2157841460","https://openalex.org/W2158727328","https://openalex.org/W2159561462","https://openalex.org/W2171512247","https://openalex.org/W4234825176"],"related_works":["https://openalex.org/W2092287139","https://openalex.org/W2134806962","https://openalex.org/W2514777534","https://openalex.org/W2791740462","https://openalex.org/W1967114686","https://openalex.org/W1987579024","https://openalex.org/W2091480327","https://openalex.org/W2034574623","https://openalex.org/W1919558603","https://openalex.org/W2075070224"],"abstract_inverted_index":{"AIMS:":[0],"During":[1],"recent":[2],"years,":[3],"two":[4,190,268],"strategies":[5,374],"of":[6,26,59,94,104,114,136,309,364,384,414],"incretin-based":[7,83,116,166],"therapy":[8,35,42,84,117,167,319],"[glucagon-like":[9],"peptide-1":[10],"(GLP-1)":[11],"receptor":[12,142,151,184,272,315,348,393],"agonism":[13],"and":[14,69,204,220,274,288,311,333,351,358,418],"dipeptidyl":[15],"peptidase-4":[16],"(DPP-4)":[17],"inhibition]":[18],"have":[19,50],"entered":[20],"the":[21,112,188,267,280,362,365,370,390,400],"market":[22],"for":[23,33,132],"pharmacological":[24],"management":[25],"type":[27,46,129,330],"2":[28,47,130,331],"diabetes.":[29],"A":[30,102],"main":[31],"indication":[32],"this":[34,60],"is":[36,338,367],"as":[37,74,76,85,118],"add-on":[38,86,119],"to":[39,63,87,120,325,376,421],"on-going":[40],"metformin":[41,55,121,326],"in":[43,66,71,79,108,126,173,178,222,236,245,266,279,327,343],"subjects":[44],"with":[45,54,82,128,181,187,270,282,313,329,345,355,379,410],"diabetes":[48,131],"who":[49],"insufficient":[51],"glycaemic":[52,67],"control":[53,68],"alone.":[56],"The":[57,171],"aim":[58],"study":[61,106,179,209,237],"was":[62,175,212,260,275],"compare":[64],"improvements":[65],"changes":[70],"body":[72,258,397],"weight,":[73],"well":[75],"adverse":[77,385],"events,":[78,386],"comparable":[80],"studies":[81,110,159],"metformin.":[88],"METHODS:":[89],"Studies":[90],"having":[91],"a":[92,139,213,263,339,380,411,419],"duration":[93],"16-30":[95,133,335],"weeks":[96,336],"were":[97,198,291,303],"identified":[98],"from":[99,306],"PubMed.":[100],"RESULTS:":[101],"total":[103],"27":[105],"groups":[107,180,191,238,269,281],"21":[109],"fulfilled":[111],"criteria":[113],"examining":[115],"at":[122],"clinically":[123],"recommended":[124],"doses":[125],"patients":[127,328],"weeks;":[134],"7":[135,146],"these":[137],"used":[138,147],"short-acting":[140],"GLP-1":[141,150,183,271,314,347,392],"agonist":[143],"(exenatide":[144],"BID),":[145],"longer":[148],"acting":[149],"agonists":[152,185,273,349,394],"(liraglutide":[153,350],"or":[154,241,250],"exenatide":[155,202,242,248,352,356],"LAR),":[156],"whereas":[157,196],"14":[158],"examined":[160],"DPP-4":[161,205,251,283,359,401],"inhibitors.":[162,206,284],"In":[163],"all":[164,208],"studies,":[165],"reduced":[168,261],"HbA1c":[169,174,219,223,344],"concentrations.":[170],"reduction":[172,342],"significantly":[176,234,277],"greater":[177,412],"long-acting":[182,346],"than":[186,244,354],"other":[189],"(both":[192,253],"p":[193,227,254],"<":[194,228,255],"0.001),":[195],"there":[197,211,337],"no":[199],"differences":[200],"between":[201,217],"BID":[203,249,357],"Across":[207],"groups,":[210],"negative":[214],"linear":[215],"correlation":[216],"baseline":[218,371],"change":[221],"(r":[224],"=":[225],"-0.70;":[226],"0.001).":[229,256],"Fasting":[230],"glucose":[231],"also":[232,395,408],"fell":[233],"more":[235,340],"given":[239,247],"liraglutide":[240],"LAR":[243],"those":[246],"inhibitors":[252,402],"Furthermore,":[257],"weight":[259,398,404],"by":[262],"similar":[264],"extent":[265],"not":[276,292,297],"altered":[278],"Lipids,":[285],"blood":[286],"pressure":[287],"heart":[289,423],"rate":[290],"reported":[293],"consistently,":[294],"which":[295],"did":[296],"allow":[298],"general":[299],"conclusions.":[300],"Adverse":[301],"events":[302],"rare,":[304],"apart":[305],"increased":[307],"incidence":[308,413],"nausea":[310],"vomiting":[312],"agonists.":[316],"CONCLUSION:":[317],"Incretin-based":[318],"efficiently":[320],"improves":[321],"glycaemia":[322],"when":[323],"added":[324],"diabetes,":[332],"within":[334],"pronounced":[341],"LAR)":[353],"inhibitors,":[360],"although":[361],"magnitude":[363],"effect":[366],"dependent":[368],"on":[369],"values.":[372],"Both":[373],"appear":[375],"be":[377],"associated":[378,409],"very":[381],"low":[382],"risk":[383],"including":[387],"hypoglycaemia.":[388],"Finally,":[389],"injectable":[391],"reduce":[396],"(whereas":[399],"are":[403,407],"neutral)":[405],"but":[406],"gastrointestinal":[415],"side":[416],"effects":[417],"tendency":[420],"increase":[422],"rate.":[424]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":17},{"year":2017,"cited_by_count":12},{"year":2016,"cited_by_count":16},{"year":2015,"cited_by_count":15},{"year":2014,"cited_by_count":37},{"year":2013,"cited_by_count":35},{"year":2012,"cited_by_count":8}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}